Although traditional chemotherapeutic drugs remains the first line option for the management of most cancer types, targeted cancer therapies are emerging as standard treatment for advanced stage cancers.
Global MEK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global MEK Inhibitors Market Opportunity Assessment: > USD 3 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 4 Drugs ( Trametinib, Binimetinib, Selumetinib, Cobimetinib)
- Approved MEK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report: https://www.kuickresearch.com/report-mek-map-kinase-inhibitor-market-size-clinical-trials-report
Although traditional chemotherapeutic drugs remains the first line option for the management of most cancer types, targeted cancer therapies are emerging as standard treatment for advanced stage cancers. MEK inhibitors are small molecule drugs which inhibits mitogen activated extracellular signal related kinase (MAPK) pathways which have critical role in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and motility. The novel MEK inhibitor decreases the growth of tumor in people with metastatic melanoma by hindering the activity of MEK and BRAF kinases.
Mekinist developed by GlaxoSmithKline was the first MEK inhibitor which was approved by FDA in 2013. The drug was initially indicated for the treatment of unresectable or metastatic melanoma in adult patients with BRAF V600E or V600K mutations. Later, the drug was also approved for the management of non-small cell lung cancer as well as anaplastic thyroid cancer. In 2020, Mekinist segment had a significant share, and this trend is expected to continue over the forecast period which is mainly due to its widespread use as monotherapy and combinational therapy in the management of wide range of cancers. Apart from this, three other MEK inhibitors have also gained approval in the market including Cotellic, Mektovi and Koselugo.
The drug Mektovi and Koselugo have recently entered the market in last two years and have shown high response rates among the patients. Researchers are currently conducting several clinical trials which are evaluating the role of these drugs in other cancers including myeloma, biliary tract cancer, ovarian cancer, thyroid cancer, and other solid tumors. For instance, Mektovi is currently present in phase-III clinical trials in patients with ovarian cancer and is currently recruiting patients. The extended approval of these drugs will drive this segment in the market for next few years.
Despite several advantages of MEK inhibitor drugs, the overall market is mainly restricted by several factors. The development of resistance to the drugs after 1-2 year of the therapy is one of the major concerns which limit the uptake of MEK inhibitors. However, extensive efforts by researchers have led to the identification of various mechanisms of resistance and a possible solution to overcome them. Several next generation MEK inhibitors are present in clinical pipeline which have shown to overcome the resistance. Apart from this, several ongoing clinical trials are evaluating the efficacy of these drugs in combination with other chemotherapeutic and immune checkpoint inhibitors. The combinational therapy will increase the efficacy of the drug against the multifactorial nature of cancer.
The global TRK inhibitor market is expected to witness high growth rates during the forecast period which is mainly attributed to the rise in prevalence of cancer associated with high research and development in this sector. Apart from this, the rates at which conventional cancer therapies are falling will further possess unmet need for the development of novel targeted therapies which will also drive the growth of market. In addition to this, the robust pipeline of MEK inhibitors and the robust clinical trials will also aid in propelling the growth of market. The key players in global MEK inhibitor market are Merck, Roche, Pfizer, AstraZeneca, Ono Pharmaceutical, and Spring Work Therapeutics.
In terms of region, North America particularly US was the leading contributor in 2020, owing to high adoption rates of MEK kinase inhibitors. The region will maintain its dominancy during the forecast period owing to their well-developed technology, increase patient base, and high investment in healthcare sector. Furthermore, the presence of large pharmaceutical companies has further fueled the research and development activities in this region. Apart from this, Europe also accounts for a key share in the market owing to high prevalence of cancer, increase in healthcare expenditure, and rising government initiatives.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366